Ali Mtoro
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ali Mtoro has a total of 67 co-authors. Here are the top co-authors by number of shared publications:
- Ali Hamad
Ifakara Health Institute, Dar es Salaam, Tanzania
2 shared publications - Claudia Daubenberger
Swiss Tropical and Public Health Institute, Allschwil, Switzerland
2 shared publications - Guillermo Alberto García
MCD Global Health, Silver Spring, USA
2 shared publications - José Raso Bijeri
Ministry of Health and Social Welfare, Equatorial Guinea (EGMOHSW), Malabo, Equatorial Guinea
2 shared publications - Kamaka Ramadhani Kassim
Ifakara Health Institute, Dar es Salaam, Tanzania
2 shared publications - Marcel Tanner
Swiss Tropical and Public Health Institute, 4123 Basel, Switzerland
2 shared publications
Latest Publications
- Open Access
- 4 June 2025
- Published by American Society of Tropical Medicine and Hygiene in The American Journal of Tropical Medicine and Hygiene
- Vol. 112 (6) , 1364-1377
Assessment of Health Status and Creation of a Registry of Potential Research Participants Aged 1.5 to 50 Years on Bioko Island, Equatorial Guinea
: A malaria control program established in 2004 on Bioko Island, Equatorial Guinea, achieved significant reductions in malaria prevalence; however, progress subsequently stalled, leading to a proposal to develop and implement a highly effective malaria vaccine to increase impact. After conducting clinical trials of Sanaria® (Rockville, MD) Plasmodium falciparum (P. falciparum) sporozite vaccines against P. falciparum malaria, which demonstrated safety and efficacy, a larger phase 3 trial was planned to support vaccine licensure for specific target populations and eventual island-wide malaria elimination. The Equatorial Guinea Pilot Study for Recruitment, Screening and Participant Registry (EGRESPAR) assessed the health status of the target population and generated a registry of eligible children and adults. Households in areas with malaria prevalence ≥15% were randomly selected, aiming to register 2,100 healthy Equatoguineans divided equally into age groups of 1.5–9, 10–17, and 18–50 years. A total of 6,493 individuals from 1,807 households, who considered themselves or their children to be healthy, completed questionnaires; 2,021 were screened using phase 3 enrollment criteria, 643 were excluded, and 1,378 were entered into the registry. Among those screened, 13.6% had Plasmodium, 1.8% had Loa loa, 4.8% had hepatitis B, 0.5% had hepatitis C, and 2.1% had HIV. Adults were twice as likely to have clinically relevant medical conditions, such as obesity, hypertension, or diabetes, meeting exclusion criteria compared to children. In conclusion, there was a significant prevalence of infections and chronic medical conditions among Bioko Island residents who considered themselves or their children to be healthy and interested in clinical research participation, particularly in adults. The EGRESPAR successfully generated a registry to support the initiation of a large-scale phase 3 vaccine trial.
- 4 June 2025
- Published by American Society of Tropical Medicine and Hygiene in The American Journal of Tropical Medicine and Hygiene
- Vol. 112 (6) , 1364-1377
Open AccessAssessment of Health Status and Creation of a Registry of Potential Research Participants Aged 1.5 to 50 Years on Bioko Island, Equatorial Guinea
: A malaria control program established in 2004 on Bioko Island, Equatorial Guinea, achieved significant reductions in malaria prevalence; however, progress subsequently stalled, leading to a proposal to develop and implement a highly effective malaria vaccine to increase impact. After conducting clinical trials of Sanaria® (Rockville, MD) Plasmodium falciparum (P. falciparum) sporozite vaccines against P. falciparum malaria, which demonstrated safety and efficacy, a larger phase 3 trial was planned to support vaccine licensure for specific target populations and eventual island-wide malaria elimination. The Equatorial Guinea Pilot Study for Recruitment, Screening and Participant Registry (EGRESPAR) assessed the health status of the target population and generated a registry of eligible children and adults. Households in areas with malaria prevalence ≥15% were randomly selected, aiming to register 2,100 healthy Equatoguineans divided equally into age groups of 1.5–9, 10–17, and 18–50 years. A total of 6,493 individuals from 1,807 households, who considered themselves or their children to be healthy, completed questionnaires; 2,021 were screened using phase 3 enrollment criteria, 643 were excluded, and 1,378 were entered into the registry. Among those screened, 13.6% had Plasmodium, 1.8% had Loa loa, 4.8% had hepatitis B, 0.5% had hepatitis C, and 2.1% had HIV. Adults were twice as likely to have clinically relevant medical conditions, such as obesity, hypertension, or diabetes, meeting exclusion criteria compared to children. In conclusion, there was a significant prevalence of infections and chronic medical conditions among Bioko Island residents who considered themselves or their children to be healthy and interested in clinical research participation, particularly in adults. The EGRESPAR successfully generated a registry to support the initiation of a large-scale phase 3 vaccine trial.
- Open Access
- 9 May 2023
- Published by American Society of Tropical Medicine and Hygiene in The American Journal of Tropical Medicine and Hygiene
- Vol. 109 (1) , 138-146
Safety and Immunogenicity of Radiation-Attenuated PfSPZ Vaccine in Equatoguinean Infants, Children, and Adults
: The radiation-attenuated Plasmodium falciparum sporozoites (PfSPZ) Vaccine has demonstrated safety and immunogenicity in 5-month-old to 50-year-old Africans in multiple trials. Except for one, each trial has restricted enrollment to either infants and children or adults < 50 years old. This trial was conducted in Equatorial Guinea and assessed the safety, tolerability, and immunogenicity of three direct venous inoculations of 1.8 × 106 or 2.7 × 106 PfSPZ, of PfSPZ Vaccine, or normal saline administered at 8-week intervals in a randomized, double-blind, placebo-controlled trial stratified by age (6–11 months and 1–5, 6–10, 11–17, 18–35, and 36–61 years). All doses were successfully administered. In all, 192/207 injections (93%) in those aged 6–61 years were rated as causing no or mild pain. There were no significant differences in solicited adverse events (AEs) between vaccinees and controls in any age group (P ≥ 0.17). There were no significant differences between vaccinees and controls with respect to the rates or severity of unsolicited AEs or laboratory abnormalities. Development of antibodies to P. falciparum circumsporozoite protein occurred in 67/69 vaccinees (97%) and 0/15 controls. Median antibody levels were highest in infants and 1–5-year-olds and declined progressively with age. Antibody responses in children were greater than in adults protected against controlled human malaria infection. Robust immunogenicity, combined with a benign AE profile, indicates children are an ideal target for immunization with PfSPZ Vaccine.
- 9 May 2023
- Published by American Society of Tropical Medicine and Hygiene in The American Journal of Tropical Medicine and Hygiene
- Vol. 109 (1) , 138-146
Open AccessSafety and Immunogenicity of Radiation-Attenuated PfSPZ Vaccine in Equatoguinean Infants, Children, and Adults
: The radiation-attenuated Plasmodium falciparum sporozoites (PfSPZ) Vaccine has demonstrated safety and immunogenicity in 5-month-old to 50-year-old Africans in multiple trials. Except for one, each trial has restricted enrollment to either infants and children or adults < 50 years old. This trial was conducted in Equatorial Guinea and assessed the safety, tolerability, and immunogenicity of three direct venous inoculations of 1.8 × 106 or 2.7 × 106 PfSPZ, of PfSPZ Vaccine, or normal saline administered at 8-week intervals in a randomized, double-blind, placebo-controlled trial stratified by age (6–11 months and 1–5, 6–10, 11–17, 18–35, and 36–61 years). All doses were successfully administered. In all, 192/207 injections (93%) in those aged 6–61 years were rated as causing no or mild pain. There were no significant differences in solicited adverse events (AEs) between vaccinees and controls in any age group (P ≥ 0.17). There were no significant differences between vaccinees and controls with respect to the rates or severity of unsolicited AEs or laboratory abnormalities. Development of antibodies to P. falciparum circumsporozoite protein occurred in 67/69 vaccinees (97%) and 0/15 controls. Median antibody levels were highest in infants and 1–5-year-olds and declined progressively with age. Antibody responses in children were greater than in adults protected against controlled human malaria infection. Robust immunogenicity, combined with a benign AE profile, indicates children are an ideal target for immunization with PfSPZ Vaccine.